Interdose Withdrawal: Symptoms Between Doses
TL;DR
- Interdose withdrawal is early withdrawal appearing between doses, before the next one is due. It happens with short half-life medications whose blood level falls far enough within a single dosing interval.
- It is most common with short-acting benzodiazepines (alprazolam, lorazepam) and short half-life antidepressants (venlafaxine, duloxetine, paroxetine) [1][2].
- The defining clue is timing: symptoms cluster in the hours before your next dose and ease within an hour or so of taking it. A true underlying anxiety disorder does not run on that schedule.
- It is routinely misread as tolerance, worsening anxiety, or proof the medication is still needed — which sometimes leads to a dose increase when the real problem is how the dose is distributed across the day.
- The usual fixes are structural rather than higher doses: splitting the same daily total into more frequent doses, or moving to a longer-acting medication that holds a steadier level [1][2].
If the worst part of your day is the two hours before your next dose — the edginess, the shakiness, the anxiety climbing for no reason — and it settles shortly after you take it, you may not be watching your anxiety disorder. You may be watching interdose withdrawal: early withdrawal surfacing between doses because the medication is clearing your system faster than the dosing schedule accounts for. It is common, frequently misidentified, and usually fixable without increasing the dose.
What is interdose withdrawal?
Every dose produces a peak, then a decline as the drug is cleared. With a long-acting medication the decline is shallow and the next dose arrives long before the level falls far. With a short-acting one, the level can drop steeply within a single dosing interval — and if it drops below what your nervous system has adapted to, withdrawal begins even though you have not missed anything and are taking exactly what was prescribed [1][2].
That is the whole phenomenon. Not a missed dose, not a reduction, not tolerance in the usual sense — just a trough deep enough to register, repeating every day on the same schedule.
People often describe it as “watching the clock” — knowing without looking that they are due, because their body has already told them.
How to tell it apart from anxiety
The symptoms overlap almost completely, which is why this gets missed. The pattern is what separates them:
| Signal | Interdose withdrawal | Underlying anxiety |
|---|---|---|
| Timing | Clusters in the hours before the next dose, most days | Tracks situations, thoughts and stressors, not the clock |
| Response to dosing | Eases within roughly an hour of taking the dose | Not reliably changed by a single dose |
| Physical features | Often tremor, sweating, nausea, sound or light sensitivity | Physical symptoms present but usually tied to anxious episodes |
| Overnight | Frequently worst on waking, after the longest gap between doses | Varies; not systematically tied to the overnight interval |
A week of dated notes — time of dose, time symptoms rise, time they settle — usually makes this obvious, and it is far more persuasive to a provider than describing it from memory.
Which medications cause it
Half-life is the whole story. The shorter the half-life relative to the dosing interval, the deeper the trough:
| Medication | Approximate half-life | Interdose risk |
|---|---|---|
| Alprazolam (Xanax) | About 11 hours | High — a classic cause, especially on twice-daily dosing |
| Lorazepam (Ativan) | About 10–20 hours | High |
| Venlafaxine (Effexor) | About 5 hours | High — often felt as afternoon or morning symptoms |
| Duloxetine (Cymbalta) | About 12 hours | Moderate to high |
| Paroxetine (Paxil) | About 21 hours | Moderate |
| Diazepam (Valium) | Long, with active metabolites | Low — which is why it is used to stabilise tapers |
| Fluoxetine (Prozac) | 4–6 days (metabolite longer) | Very low |
Half-lives are approximate adult averages [3]; individual metabolism varies, which is why two people on the same dose of the same drug can have entirely different experiences of the same schedule.
Why it gets mistaken for needing a higher dose
From the outside, interdose withdrawal looks exactly like the medication no longer working. The patient reports worsening anxiety despite taking it as prescribed. The intuitive response is to increase the dose.
Sometimes that helps briefly — a higher peak takes longer to fall through the same range. But it does not address the shape of the curve, and on a short-acting drug the trough returns, now from a higher starting point. That is the loop by which people end up on escalating doses of a medication that never stopped being cleared quickly.
The question worth asking is not “is this dose big enough?” but “is this dose spread across the day in a way this drug can sustain?”
What actually fixes it
These are provider decisions — the point of knowing them is to have a more precise conversation, not to self-adjust:
- Redistribute the same daily total. Splitting a twice-daily dose into three or four smaller ones keeps the level steadier without increasing the amount taken. This is often the entire solution [1].
- Switch to something longer-acting. For benzodiazepines this typically means moving part or all of the dose to diazepam, which is standard practice before tapering a short-acting benzodiazepine [1][2]. For antidepressants, a longer half-life agent smooths the same problem.
- Move to an extended-release form where one exists, which flattens the peaks and troughs of the same drug.
- Do not skip doses to “save” medication. Skipping deepens exactly the trough that is causing the symptoms — the mechanism is the same one that makes every-other-day tapering backfire.
If you are tapering a short-acting benzodiazepine, stabilising interdose symptoms usually has to come before reductions resume — see how fast is too fast to taper a benzodiazepine.
What providers should know
Interdose withdrawal is a dosing-interval problem masquerading as a treatment-response problem, and the cost of misreading it is dose escalation on exactly the agents where that is least desirable. The discriminators are cheap to elicit: symptom onset clustered pre-dose, relief within about an hour of dosing, worst-on-waking after the overnight gap, and physical features disproportionate to the situational context [1][2].
Practically: ask for a week of timed symptom-versus-dose notes before adjusting anything; consider redistributing the existing daily total across more frequent doses as the first-line change; and for short-acting benzodiazepines, consider long-acting substitution to stabilise before any taper resumes, consistent with the standard withdrawal literature and the 2025 ASAM tapering guidance [1][2][4]. Class-specific frameworks are in our benzodiazepine deprescribing guide, with taper construction covered in The Deprescriber’s Playbook.
Related reading: tapering off Ativan, tapering off Xanax, and what brain zaps are. Providers who work with structured tapers are listed in the MyDeprescriber directory.
Frequently asked questions
Withdrawal symptoms that appear between scheduled doses, before the next one is due, because a short-acting medication’s blood level falls below what your nervous system has adapted to within a single dosing interval. It is not caused by missing doses or reducing them — it happens while taking the medication exactly as prescribed, and it repeats on the same daily schedule.
Timing is the clearest discriminator. Interdose withdrawal clusters in the hours before your next dose, is often worst on waking after the long overnight gap, and eases within roughly an hour of taking the dose. Underlying anxiety tracks situations and thoughts rather than the clock, and is not reliably switched off by a single dose. A week of timed notes usually makes the pattern obvious.
Short half-life drugs, most notably alprazolam and lorazepam among benzodiazepines, and venlafaxine, duloxetine and paroxetine among antidepressants. Long-acting medications such as diazepam and fluoxetine rarely cause it, because their levels barely fall between doses — which is exactly why they are used to stabilise difficult tapers.
Usually not. It generally means the same daily amount is distributed in a way the drug’s half-life cannot sustain. Increasing the dose raises the peak but leaves the trough, so symptoms tend to return from a higher baseline — which is how escalation happens. The more common fixes are splitting the existing total into more frequent doses, or moving to a longer-acting medication.
That is often the right answer, but it should be a provider’s decision rather than a self-adjustment — redistributing a controlled medication changes your supply timing and can create refill problems, and the appropriate split depends on the drug. Bring a week of timed symptom notes and ask specifically about dividing the current daily total into smaller, more frequent doses.
No. It reflects physical dependence, which develops predictably with regular use of these medications and is not the same as addiction — it is not about craving, compulsion or use despite harm. Dependence can develop taking a medication exactly as prescribed, and its presence says nothing about your relationship with the drug.
Medical disclaimer. This article is educational information for patients and clinicians. It is not medical advice for any individual person, and it does not replace the judgment of the provider who knows your history. Never stop or change a prescribed medication on your own, because abrupt discontinuation of some drug classes can cause serious withdrawal, rebound, or return of the underlying condition. Talk with your provider first. If you or someone you know is in crisis, call or text 988 in the United States to reach the Suicide and Crisis Lifeline.
References
- Ashton CH. Benzodiazepines: How They Work and How to Withdraw (“The Ashton Manual”). 2002. Link
- Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. Wiley Blackwell; 2024. Link
- Hiemke C, Baumann P, Bergemann N, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62. Link
- American Society of Addiction Medicine. Clinical Practice Guideline on Benzodiazepine Tapering. 2025. Link
Want more evidence-based deprescribing in your Google results?